Monday, October 01, 2007


Hythiam says investigators observe significant reduction in methamphetamine cravings and use in study of component of it's PROMETA treatment program published in Mayo Clinic Proceedings Journal. Hythiam announced that the Mayo Clinic Proceedings medical journal published in their October installment, an open-label study by Dr. Harold C. Urschel, III, M.D., M.M.A. of the pharmacological component of the PROMETA Treatment Program for methamphetamine dependence. The study found that this component of the PROMETA Treatment Program persistently reduced methamphetamine cravings and use.

No comments:

Native American Advisors CHIPPEWA PARTNERS